AIM
ARRY

Advantage Investment Management’s Array Biopharma Inc ARRY Stock Holding History

Advantage Investment Management’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-632
Closed -$10K – 1068
2018
Q1 		$10K Buy
+632
New +$10.1K ﹤0.01% 683

Other funds holding ARRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Advantage Investment Management's ARRY Position: Q2 2018 in Review

Advantage Investment Management sold out of Array Biopharma Inc (ARRY) in Q2 2018, closing a stake of 632 shares — an estimated $10K sold.

Advantage Investment Management first reported a position in ARRY in Q1 2018 and held it in 1 quarter. The position peaked at $10K in Q1 2018. 223 funds tracked by Wall St. Rank hold ARRY as of Q2 2018.

  • Advantage Investment Management reported no remaining Array Biopharma Inc position as of Q2 2018 after selling out during the quarter.
  • Advantage Investment Management sold 632 Array Biopharma Inc shares in Q2 2018, an estimated $10K.
  • Advantage Investment Management first reported a position in Array Biopharma Inc in Q1 2018 and held it in 1 quarter.
  • Advantage Investment Management's Array Biopharma Inc position peaked at $10K in Q1 2018.
  • 223 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q2 2018.

Based on Advantage Investment Management's 13F filing for Q2 2018, filed 13 Aug 2018.